Latest News
& Press Releases
Browse the latest news from BioSpace, and press releases from around the industry. Want to filter by date, keyword, and more? Search here.
TOP STORIES
AC Immune’s Phase II Lauriet study of investigational anti-Tau monoclonal antibody, semorinemab, in mild-to-moderate Alzheimer’s disease (AD), only met one endpoint.
The company is investigating the death of a 75-year-old woman who died of ARIA while receiving Aduhelm.
Celares and Mission Bio are part of the rapidly evolving push to create and characterize the superhuman powers cells can be endowed with.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
Eric Ostertag, CEO of Poseida Therapeutics, believes the future of CAR-T programs is with allogeneic approaches and not autologous.
Cell therapy veteran Christina Coughlin is taking over the reins of the privately-held company developing natural killer immune cells to battle cancer.
A research team at the University of North Carolina – Chapel Hill (UNC) and Duke University, in Durham, NC identified an antibody that attacks SARS-CoV-2 and its variants and other types of coronaviruses.
Exavir Therapeutics announced that it was able to eliminate HIV from human cells with lipid nanoparticle (LNP)-delivered Tat-targeted CRISPR-Cas9.
Pfizer and BioNTech requested the FDA authorize booster shots for their COVID-19 vaccine for all adults 18 years and older, presenting data not available in September.
The drug for treatment-resistant depression reportedly demonstrated significant improvement in patients at its highest dose of 25 mg. Here’s more about it.
Angany entered into collaboration for a series of preclinical studies that will evaluate the safety and efficacy of BP/AH-01, Angany’s lead peanut allergy biological candidate.
Public Citizen urged NIH director Dr. Francis Collins to clarify the NIH’s role in Moderna’s vaccine publicly and explain what he plans to ensure that federal scientists are credited for their work.